Intero Biosystems wants drugmakers to test on mini human intestines, not animals
Intero Biosystems develops human intestinal organoids to test drugs and compounds, aiming to reduce reliance on animal testing in drug development.
Intelligence analysis by Qwen 2.5 (3B)
Intero Biosystems is developing human intestinal organoids to test drugs and compounds, aiming to reduce reliance on animal testing in drug development.
Intero Biosystems makes tiny human intestines in the lab to test drugs, so they don't need to use animals anymore.
Analysis
Human Intestinal Organoids
Intero Biosystems uses human intestinal organoids derived from induced pluripotent stem cells to mimic the human gut and test drugs and compounds.
Regulatory Changes
Recent regulatory changes have encouraged the use of non-animal testing methods, including organoids, to support regulatory submissions.
Validation Process
Intero Biosystems is in the second stage of a three-stage validation process to show that its GastroScreen model can predict human drug responses more accurately than existing animal or cell-based models.
Key points
- Intero Biosystems develops human intestinal organoids to test drugs and compounds
- Regulatory changes have encouraged the use of non-animal testing methods, including organoids
- Intero Biosystems is in the second stage of a three-stage validation process to show its GastroScreen model can predict human drug responses more accurately than existing animal or cell-based models
Intero Biosystems' human intestinal organoids could lead to faster and more accurate drug development, potentially saving lives and reducing animal suffering.
Intero Biosystems' human intestinal organoids may not be ready for widespread use yet, and there could be challenges in scaling production and personalizing the models.
